A Statistical Evaluation of Rules for Biochemical Failure After Radiotherapy in Men Treated for Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 5, 2009, Pages 1357-1363

  Bellera, Carine A ^a,b   Hanley, James A ^b   Joseph, Lawrence ^b   Albertsen, Peter C ^c  

^a INSTITUT BERGONIÉ   (France)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Prostate cancer; PSA failure; Radiotherapy; Sensitivity; Specificity

Indexed keywords

AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGIES; BAYESIAN; BIOCHEMICAL FAILURE; CHANGE-POINTS; DATA SETS; DIFFERENT FREQUENCY; GOLD STANDARDS; LOCALIZED PROSTATE CANCER; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; PSA DOUBLING TIME; PSA FAILURE; RANDOM VARIATION; RULES BASED; SENSITIVITY AND SPECIFICITY; SIMULATION PROCESS; STATISTICAL EVALUATION;

FUNCTION EVALUATION; PATIENT MONITORING; RADIOTHERAPY; SIMULATORS; TUMORS;

PEELING;

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; AGED; ARTICLE; CANCER LOCALIZATION; CANCER REGISTRY; CLINICAL EVALUATION; COHORT ANALYSIS; FOLLOW UP; GOLD STANDARD; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SIMULATION;

AGED; BAYES THEOREM; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SOCIETIES, MEDICAL; TIME FACTORS; TREATMENT FAILURE; UNITED STATES;

EID: 71649106174     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.01.013     Document Type: Article

References (18)

1. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
2. Buyyounouski M.K., Hanlon A.L., Eisenberg D.F., et al. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1455-1462
3. Kuban D.A., Thames H.D., and Shipley W.U. Defining recurrence after radiation for prostate cancer. J Urol 173 (2005) 1871-1878
4. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
5. Horwitz E.M., Levy L.B., Thames H.D., et al. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: A multiinstitutional pooled analysis. Cancer 107 (2006) 1496-1502
6. Horwitz E.M., Thames H.D., Kuban D.A., et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. J Urol 173 (2005) 797-802
7. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
8. Horwitz E.M., Uzzo R.G., Hanlon A.L., et al. Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. J Urol 169 (2003) 2153-2157
9. Critz F.A. A standard definition of disease freedom is needed for prostate cancer: Undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol 167 (2002) 1310-1313
10. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. J Am Med Assoc 281 (1999) 1598-1604
11. Albertsen P.C., Hanley J.A., Penson D.F., et al. 13-Year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 177 (2007) 932-936
12. Bellera C.A., Hanley J.A., Joseph L., and Albertsen P.C. Detecting Trends in Noisy Data Series: Application to Biomarker Series. Am J Epidemiol 167 (2008) 1130-1139
13. Bellera C.A., Hanley J.A., Joseph L., and Albertsen P.C. Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer. Ann Epidemiol 18 (2008) 270-282
14. Hanlon A.L., Diratzouian H., and Hanks G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 297-303
15. Kestin L.L., Vicini F.A., Ziaja E.L., et al. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer 86 (1999) 1557-1566
16. Coen J.J., Chung C.S., Shipley W.U., and Zietman A.L. Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: Results from a 10-year cohort analysis. Int J Radiat Oncol Biol Phys 57 (2003) 621-628
17. Eastham J.A., Riedel E., Scardino P.T., et al. Variation of serum prostate-specific antigen levels: An evaluation of year-to-year fluctuations. J Am Med Assoc 289 (2003) 2695-2700
18. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J Am Med Assoc 267 (1992) 2215-2220